---
schema_version: "secwatch.filing_event.v1"
accession: "0001810182-25-000006"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2025-09-12T23:59:59+00:00"
generated_at: "2026-05-17T06:45:38.334870+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology: CMO Alan Sandler resigns, Barbara Klencke appointed Interim CMO; Nasdaq compliance regained

## Summary
- Alan Sandler resigns as CMO effective Sep 26, 2025, returns to Board as director.
- Barbara Klencke steps down from Board to become Interim CMO effective Sep 17, 2025.
- ALX regained Nasdaq minimum bid price compliance (closing bid >= $1 for 10 consecutive days through Sep 4, 2025).
- Board committee changes: R&D committee paused; new Audit, Compensation, and Governance committee assignments approved.

## SEC filing metadata
- accession: 0001810182-25-000006
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2025-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000181018225000006/0001810182-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000181018225000006/alxo-20250911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001810182-25-000006
- JSON: https://secwatch.observer/filing/0001810182-25-000006.json
- Plain text: https://secwatch.observer/filing/0001810182-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.